MCF Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

MCF Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.8K	Buy	243 +132	+119%	+$31.1K	﹤0.01%	592
2026 Q1	$22.2K	Buy	+111	New	+$22K	﹤0.01%	792

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCF Advisors's LGND Position: Q2 2026 in Review

MCF Advisors increased its Ligand Pharmaceuticals (LGND) stake by 119% in Q2 2026, buying an estimated $31.1K and bringing the position to 243 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #592.

MCF Advisors first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

MCF Advisors held 243 shares of Ligand Pharmaceuticals worth $76.8K as of Q2 2026.
MCF Advisors bought 132 Ligand Pharmaceuticals shares in Q2 2026, an estimated $31.1K.
Ligand Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #592 holding.
MCF Advisors first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.